Published in Carcinogenesis on December 06, 2005
Methylating agents and DNA repair responses: Methylated bases and sources of strand breaks. Chem Res Toxicol (2006) 2.25
The FANCJ/MutLalpha interaction is required for correction of the cross-link response in FA-J cells. EMBO J (2007) 1.86
DNA replication fidelity and cancer. Semin Cancer Biol (2010) 1.69
Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens. Mol Cell Proteomics (2011) 1.53
Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med (2009) 1.49
DNA mismatch-specific targeting and hypersensitivity of mismatch-repair-deficient cells to bulky rhodium(III) intercalators. Proc Natl Acad Sci U S A (2006) 1.48
Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci (2009) 1.44
Direct visualization of asymmetric adenine-nucleotide-induced conformational changes in MutL alpha. Mol Cell (2008) 1.38
Interactions of human mismatch repair proteins MutSalpha and MutLalpha with proteins of the ATR-Chk1 pathway. J Biol Chem (2009) 1.21
hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis. J Biol Chem (2011) 1.21
Human MutL-complexes monitor homologous recombination independently of mismatch repair. DNA Repair (Amst) (2008) 1.01
O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. Cell Death Dis (2013) 0.98
Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomide-induced senescence in glioma cells. BMC Cancer (2013) 0.96
Analysis of monensin sensitivity in Toxoplasma gondii reveals autophagy as a mechanism for drug induced death. PLoS One (2012) 0.94
Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma. Oncotarget (2013) 0.94
The "two-faced" effects of reactive oxygen species and the lipid peroxidation product 4-hydroxynonenal in the hallmarks of cancer. Cancers (Basel) (2010) 0.93
Insights into protein - DNA interactions, stability and allosteric communications: a computational study of mutSα-DNA recognition complexes. J Biomol Struct Dyn (2012) 0.92
Structural, molecular and cellular functions of MSH2 and MSH6 during DNA mismatch repair, damage signaling and other noncanonical activities. Mutat Res (2013) 0.91
The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell cycle control and apoptosis: implications for pathogenesis, progression and therapy of cancer. J Mol Histol (2006) 0.91
An MLH1 mutation links BACH1/FANCJ to colon cancer, signaling, and insight toward directed therapy. Cancer Prev Res (Phila) (2010) 0.89
Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells. Mol Biol Cell (2009) 0.89
Transcriptome analysis of a rotenone model of parkinsonism reveals complex I-tied and -untied toxicity mechanisms common to neurodegenerative diseases. PLoS One (2012) 0.89
Ovarian cancer: in search of better marker systems based on DNA repair defects. Int J Mol Sci (2013) 0.87
Disruption of a mitochondrial MutS DNA repair enzyme homologue confers drug resistance in the parasite Toxoplasma gondii. Mol Microbiol (2009) 0.87
Oligonucleotide-mediated gene targeting in human hepatocytes: implications of mismatch repair. Oligonucleotides (2008) 0.87
Apoptotic function of human PMS2 compromised by the nonsynonymous single-nucleotide polymorphic variant R20Q. Proc Natl Acad Sci U S A (2008) 0.87
The molecular origin of the MMR-dependent apoptosis pathway from dynamics analysis of MutSα-DNA complexes. J Biomol Struct Dyn (2012) 0.86
Alkylation damage causes MMR-dependent chromosomal instability in vertebrate embryos. Nucleic Acids Res (2008) 0.86
Chaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53-dependent pathway in cisplatin-resistant ovarian cancer cells. Cancer Lett (2014) 0.85
Differential cellular responses to prolonged LDR-IR in MLH1-proficient and MLH1-deficient colorectal cancer HCT116 cells. Clin Cancer Res (2009) 0.85
MutS homologue hMSH5: role in cisplatin-induced DNA damage response. Mol Cancer (2012) 0.85
Absence of MGMT promoter methylation in endometrial cancer. Gynecol Oncol (2008) 0.85
Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells. J Biomed Res (2010) 0.84
Molecular signaling mechanisms of apoptosis in hereditary non-polyposis colorectal cancer. World J Gastrointest Pathophysiol (2012) 0.84
Aberrant methylation of different DNA repair genes demonstrates distinct prognostic value for esophageal cancer. Dig Dis Sci (2011) 0.84
Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity. Nucleic Acids Res (2013) 0.84
The antibiotic monensin causes cell cycle disruption of Toxoplasma gondii mediated through the DNA repair enzyme TgMSH-1. Antimicrob Agents Chemother (2010) 0.83
Nuclear reorganization of DNA mismatch repair proteins in response to DNA damage. DNA Repair (Amst) (2009) 0.83
MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition. Br J Cancer (2009) 0.81
Msh6 protects mature B cells from lymphoma by preserving genomic stability. Am J Pathol (2010) 0.80
MLH1 mediates PARP-dependent cell death in response to the methylating agent N-methyl-N-nitrosourea. Br J Cancer (2009) 0.80
Oxidative stress generated during monensin treatment contributes to altered Toxoplasma gondii mitochondrial function. Sci Rep (2016) 0.79
Binding of MutS protein to oligonucleotides containing a methylated or an ethylated guanine residue, and correlation with mutation frequency. Mutat Res (2007) 0.79
DNA mismatch repair gene MLH1 induces apoptosis in prostate cancer cells. Oncotarget (2014) 0.79
Metronomic treatment of temozolomide increases anti-angiogenicity accompanied by down-regulated O(6)-methylguanine-DNA methyltransferase expression in endothelial cells. Exp Ther Med (2011) 0.78
Non-canonical actions of mismatch repair. DNA Repair (Amst) (2015) 0.76
Mismatch repair system decreases cell survival by stabilizing the tetraploid G1 arrest in response to SN-38. Int J Cancer (2010) 0.76
The homologous recombination protein RAD51D mediates the processing of 6-thioguanine lesions downstream of mismatch repair. Mol Cancer Res (2011) 0.76
Restoration of mismatch repair functions in human cell line Nalm-6, which has high efficiency for gene targeting. PLoS One (2013) 0.76
MSH2 and CXCR4 involvement in malignant VIPoma. World J Surg Oncol (2012) 0.75
Functional role of DNA mismatch repair gene PMS2 in prostate cancer cells. Oncotarget (2015) 0.75
Human MutL homolog 1 immunoexpression in oral leukoplakia and oral squamous cell carcinoma: A prospective study in Indian population. J Oral Maxillofac Pathol (2016) 0.75
Effects of aspirin on colorectal cancer related to lynch syndrome. J Adv Pract Oncol (2012) 0.75
A PLAC8-containing protein from an endomycorrhizal fungus confers cadmium resistance to yeast cells by interacting with Mlh3p. Nucleic Acids Res (2011) 0.75
Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells. PLoS One (2017) 0.75
Novel Implications in Molecular Diagnosis of Lynch Syndrome. Gastroenterol Res Pract (2017) 0.75
Cellular response to alkylating agent MNNG is impaired in STAT1-deficients cells. J Cell Mol Med (2016) 0.75
NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair. Blood Cancer J (2015) 0.75
Effect of cell cycle duration on somatic evolutionary dynamics. Evol Appl (2017) 0.75
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol (2007) 3.86
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. Hum Mol Genet (2012) 3.07
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04
Comparison of plethysmographic and helium dilution lung volumes: which is best for COPD? Chest (2009) 2.98
Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl (2005) 2.63
Case scenario: acute postoperative negative pressure pulmonary edema. Anesthesiology (2010) 2.54
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol (2007) 2.48
Health risk of chrysotile revisited. Crit Rev Toxicol (2013) 2.45
DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst (2005) 2.43
CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res (2005) 2.11
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res (2007) 2.08
Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther (2011) 1.96
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res (2002) 1.91
Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology (2014) 1.91
The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant (2005) 1.90
A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res (2008) 1.89
Thrombocytopenia associated with chronic liver disease. J Hepatol (2008) 1.89
Asthma outcomes: biomarkers. J Allergy Clin Immunol (2012) 1.88
Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther (2003) 1.87
miRNA malfunction causes spinal motor neuron disease. Proc Natl Acad Sci U S A (2010) 1.83
CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett (2008) 1.75
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther (2011) 1.70
Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol (2008) 1.66
The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res (2004) 1.65
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61
Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res (2006) 1.53
Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res (2012) 1.52
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. Liver Transpl (2009) 1.46
Progressive granulomatous pneumonitis in response to cosmetic subcutaneous silicone injections in a patient with HIV-1 infection: case report and review of the literature. Arch Pathol Lab Med (2012) 1.46
The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol (2004) 1.41
Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases. Nat Chem Biol (2013) 1.38
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36
Recommendations for improved acute pain services: Canadian collaborative acute pain initiative. Pain Res Manag (2004) 1.33
ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res (2008) 1.33
Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Updat (2004) 1.32
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res (2011) 1.28
Improved validation of peptide MS/MS assignments using spectral intensity prediction. Mol Cell Proteomics (2006) 1.28
DNA methylation as a long-term biomarker of exposure to tobacco smoke. Epidemiology (2013) 1.28
Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS One (2007) 1.22
Spirometry testing standards in spinal cord injury. Chest (2003) 1.22
Antigenic diversity is generated by distinct evolutionary mechanisms in African trypanosome species. Proc Natl Acad Sci U S A (2012) 1.22
Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res (2005) 1.20
Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis (2005) 1.17
Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res (2011) 1.15
The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer (2009) 1.15
The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin Cancer Res (2004) 1.15
Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev (2011) 1.14
Genome screen to detect linkage to intracranial aneurysm susceptibility genes: the Familial Intracranial Aneurysm (FIA) study. Stroke (2008) 1.10
Determinants of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC in chronic spinal cord injury. Arch Phys Med Rehabil (2006) 1.09
Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert Rev Mol Med (2004) 1.08
A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2007) 1.07
Microcalorimetric study of ammonia chemisorption on H3PW12O40 supported onto mesoporous synthetic carbons and SBA-15. Langmuir (2006) 1.05
Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol Oncol (2005) 1.04
Clinical ventilator adjustments that improve speech. Chest (2003) 1.04
Growth of Rhodospirillum rubrum on synthesis gas: conversion of CO to H2 and poly-beta-hydroxyalkanoate. Biotechnol Bioeng (2007) 1.04
Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann Surg (2005) 1.03
Declining expression of a single epithelial cell-autonomous gene accelerates age-related thymic involution. Aging Cell (2010) 1.03
High-throughput gene discovery in the rat. Genome Res (2004) 1.02
Guidelines and considerations for conducting experiments using tissue microarrays. Histopathology (2013) 1.02
Diagnostic radiation exposure in pediatric trauma patients. J Trauma (2011) 1.02
Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours. Int J Cancer (2006) 1.00
On the histone lysine methyltransferase activity of fungal metabolite chaetocin. J Med Chem (2013) 0.99
Alignment hierarchies: engineering architecture from the nanometre to the micrometre scale. J R Soc Interface (2010) 0.99
Dyspnea during daily activities in chronic spinal cord injury. Arch Phys Med Rehabil (2005) 0.99
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet (2013) 0.99
On the determination of the stereochemistry of semisynthetic natural product analogues using chiroptical spectroscopy: desulfurization of epidithiodioxopiperazine fungal metabolites. Chemistry (2011) 0.98
Safety of large-volume thoracentesis. Conn Med (2010) 0.98
Interference risk and the function of dynamic shifts in calling in the gray treefrog (Hyla versicolor). J Comp Psychol (2008) 0.98
A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl (2011) 0.97
Outcomes in Adults With Acute Liver Failure Between 1998 and 2013: An Observational Cohort Study. Ann Intern Med (2016) 0.97
Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response? Ann N Y Acad Sci (2003) 0.94
Dual repair modulation reverses Temozolomide resistance in vitro. Mol Cancer Ther (2004) 0.94
Mechanical signals and IGF-I gene splicing in vitro in relation to development of skeletal muscle. J Cell Physiol (2005) 0.93
Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome. Cancer Epidemiol Biomarkers Prev (2013) 0.92
Genome screen in familial intracranial aneurysm. BMC Med Genet (2009) 0.92
Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands. BMC Bioinformatics (2008) 0.91
Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin Cancer Res (2013) 0.91
Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX. Oncogene (2003) 0.91
Longitudinal change in FEV1 and FVC in chronic spinal cord injury. Am J Respir Crit Care Med (2008) 0.90
Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10. Cancer Res (2013) 0.89
Matrix stiffness and serum concentration effects matrix remodelling and ECM regulatory genes of human bone marrow stem cells. J Tissue Eng Regen Med (2008) 0.89
Prevention of vascular access hand ischemia using the axillary artery as inflow. J Vasc Surg (2013) 0.89
Alcohol use associated with cervical spinal cord injury. J Spinal Cord Med (2004) 0.89
Effect of a 10-week strength training program and recovery drink on body composition, muscular strength and endurance, and anaerobic power and capacity. Nutrition (2004) 0.89
Bilateral oculosympathetic paresis associated with loss of nocturnal melatonin secretion in patients with spinal cord injury. J Spinal Cord Med (2005) 0.88
Micro-structured materials and mechanical cues in 3D collagen gels. Methods Mol Biol (2011) 0.88
Early vs. delayed cerebral infarction after aneurysm repair after subarachnoid hemorrhage. Neurosurgery (2013) 0.87
HOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemia. Carcinogenesis (2006) 0.87
Multi-organ transplantation: is there a protective effect against acute and chronic rejection? J Heart Lung Transplant (2005) 0.87
Effect of NT-4 and BDNF delivery to damaged sciatic nerves on phenotypic recovery of fast and slow muscles fibres. Eur J Neurosci (2003) 0.87
A comparative study of the intestinal microbiota of healthy horses and those suffering from equine grass sickness. Vet Microbiol (2002) 0.87
Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception (2009) 0.87
Extended-donor criteria liver allografts. Semin Liver Dis (2006) 0.87